oxybutynin (ditropan) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Oxybutynin is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin relaxes bladder smooth muscle. Oxybutynin exhibits only one-fifth of the anticholinergic activity of atropine on the rabbit detrusor muscle, but four to ten times the antispasmodic activity. Antimuscarinic activity resides predominantly in the R-isomer. Oxybutynin exerts a direct antispasmodic effect on smooth muscle and inhibits the muscarinic action of acetylcholine on smooth muscle. No blocking effects occur at skeletal neuromuscular junctions or autonomic ganglia (antinicotinic effects). By inhibiting particularily the M1 and M2 receptors of the bladder, detrusor activity is markedly decreased.   NCATS

Chemistry

  • SMILES: CCN(CC)CC#CCOC(=O)C(O)(C1CCCCC1)c2ccccc2
  • InChIKey: XIQVNETUBQGFHX-UHFFFAOYSA-N
  • Mol. Mass: 357.49
  • ALogP: 3.34
  • ChEMBL Molecules:
    oxybutynin  
    oxybutynin chloride  
More Chemistry

Pharmacology

Drug Pricing (per unit)

Australia

$0.0306 - $19.4213

United States

$0.0451 - $81.1550
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

4-diethylamino-2-butinyl alpha-cyclohexylmandelat | 4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate | 4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate | 4-diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate | 4-(diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester | 5058 | anturol | apo-oxybutynin | benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester | contimin | contimin 2.5 | contimin 5 | cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester | cystonorm | cystrin | ditropan | ditropan xl | dresplan | dridase | driptane | gelnique | gen-oxybutynin | kentera | lyrinel xl | mj-4309-1 | novo-oxybutynin | nu-oxybutyn | oxibutinina | oxyb abz | oxybugamma | oxybutin holsten | oxybuton | oxybutynin | oxybutynin al | oxybutynin azu | oxybutynin chloride | oxybutynin darifenacin | oxybutynine | oxybutynin hcl | oxybutynin heumann | oxybutynin hexal | oxybutynin hydrochloride | oxybutynin-puren | oxybutynin-ratiopharm | oxybutynin stada | oxybutyninum | oxybutynin von ct | oxymedin | oxytrol | oxytrol for women | pms-oxybutynin | pollakisu | promictuline | renamel | ryol | spasmex oxybutynin | spasyt | tavor | urimin | zatur

Organizations (132)

Research & Development (93)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (44)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (38)

Approved Indications (2)


 

Urinary Bladder, Neurogenic (approved 1975)

Urinary Bladder, Overactive

Experimental Indications - Clinical Trial Phases 1-4 (38)


 

Autonomic Agents (Phase 2)

Breast Neoplasms (Phase 3)

Cholinergic Antagonists (Phase 2)

Cognition (Phase 4)

Cognitive Dysfunction (Phase 2)

Cystitis (Phase 4)

Diabetes Mellitus (Phase 3)

Down Syndrome (Phase 2)

Drugs, Investigational (Phase 2)

Healthy Volunteers (Phase 2)

Heating (Early Phase 1)

Hot Flashes (Phase 3)

Hyperhidrosis (Phase 4)

Male Urogenital Diseases (Phase 2)

Memory (Phase 4)

Menopause (Phase 2)

Multiple Sclerosis (Phase 4)

Nasal Obstruction (Phase 2)

Nocturnal Enuresis (Phase 3)

Parasympatholytics (Phase 2)

Prostatic Neoplasms (Phase 2)

Quality of Life (Phase 4)

Rhinitis, Allergic, Seasonal (Phase 2)

Rhinorrhea (Phase 2)

Sialorrhea (Phase 2)

Sjogren's Syndrome (Phase 4)

Skin Diseases (Phase 2)

Sleep Apnea, Obstructive (Phase 2/Phase 3)

Sleep Apnea Syndromes (Phase 1/Phase 2)

Spinal Cord Diseases (Phase 4)

Spinal Cord Injuries (Phase 4)

Sweat Gland Diseases (Phase 2)

Urinary Bladder (Phase 4)

Urinary Bladder, Neurogenic (Phase 4)

Urinary Bladder, Overactive ()

Urinary Incontinence (Phase 4)

Urinary Incontinence, Urge (Phase 4)

Urination Disorders (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 84
  • # of Trial Organizations: 93

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue